Literature DB >> 20435409

Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.

Alicia M Mihaliak1, Candace A Gilbert, Li Li, Marie-Claire Daou, Richard P Moser, Andrew Reeves, Brent H Cochran, Alonzo H Ross.   

Abstract

Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea. We developed an in vitro recovery model using neurosphere cultures to analyze the efficacy of chemotherapy treatments, and tested whether glioblastoma neurosphere-initiating cells are resistant. Concentrations of chemotherapy drugs that inhibit neurosphere formation are similar to clinically relevant doses. Some lines underwent a transient cell cycle arrest and a robust recovery of neurosphere formation. These results indicate that glioblastoma neurospheres can regrow after treatment with chemotherapy drugs. This neurosphere recovery assay will facilitate studies of chemo-resistant subpopulations and methods to enhance glioblastoma therapy. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435409      PMCID: PMC2914162          DOI: 10.1016/j.canlet.2010.04.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  50 in total

1.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Authors:  W P Roos; L F Z Batista; S C Naumann; W Wick; M Weller; C F M Menck; B Kaina
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

Review 2.  A self-renewal assay for cancer stem cells.

Authors:  Michael F Clarke
Journal:  Cancer Chemother Pharmacol       Date:  2005-11       Impact factor: 3.333

3.  Purification of a pluripotent neural stem cell from the adult mouse brain.

Authors:  R L Rietze; H Valcanis; G F Brooker; T Thomas; A K Voss; P F Bartlett
Journal:  Nature       Date:  2001-08-16       Impact factor: 49.962

4.  CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.

Authors:  Jian Wang; Per Ø Sakariassen; Oleg Tsinkalovsky; Heike Immervoll; Stig Ove Bøe; Agnete Svendsen; Lars Prestegarden; Gro Røsland; Frits Thorsen; Linda Stuhr; Anders Molven; Rolf Bjerkvig; Per Ø Enger
Journal:  Int J Cancer       Date:  2008-02-15       Impact factor: 7.396

Review 5.  Cancer stem cells: cell culture, markers, and targets for new therapies.

Authors:  Candace A Gilbert; Alonzo H Ross
Journal:  J Cell Biochem       Date:  2009-12-01       Impact factor: 4.429

Review 6.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes.

Authors:  B A Reynolds; W Tetzlaff; S Weiss
Journal:  J Neurosci       Date:  1992-11       Impact factor: 6.167

8.  Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.

Authors:  Luís F Z Batista; Wynand P Roos; Markus Christmann; Carlos F M Menck; Bernd Kaina
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

9.  Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids.

Authors:  W Günther; E Pawlak; R Damasceno; H Arnold; A J Terzis
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

10.  CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent.

Authors:  Yirui Sun; Weiqing Kong; Anna Falk; Jin Hu; Liangfu Zhou; Steve Pollard; Austin Smith
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

View more
  16 in total

1.  Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.

Authors:  Candace A Gilbert; Marie-Claire Daou; Richard P Moser; Alonzo H Ross
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

2.  Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.

Authors:  Alena Cristina Jaime-Ramirez; Nina Dmitrieva; Ji Young Yoo; Yeshavanth Banasavadi-Siddegowda; Jianying Zhang; Theresa Relation; Chelsea Bolyard; Jeffrey Wojton; Balveen Kaur
Journal:  J Gene Med       Date:  2017-03       Impact factor: 4.565

3.  Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of glioblastoma.

Authors:  Huailei Liu; Dayong Han; Yaohua Liu; Xu Hou; Jianing Wu; Huadong Li; Jie Yang; Chen Shen; Guang Yang; Changyu Fu; Xianfeng Li; Hui Che; Jing Ai; Shiguang Zhao
Journal:  J Neurooncol       Date:  2013-02-08       Impact factor: 4.130

4.  Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.

Authors:  Jilian R Melamed; Stephen A Ioele; Ariel J Hannum; Violet M Ullman; Emily S Day
Journal:  Mol Pharm       Date:  2018-10-11       Impact factor: 4.939

5.  Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.

Authors:  Dagmar Beier; Beate Schriefer; Konstantin Brawanski; Peter Hau; Joachim Weis; Jörg B Schulz; Christoph P Beier
Journal:  J Neurooncol       Date:  2012-04-29       Impact factor: 4.130

6.  Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.

Authors:  Andrea Schäfer; Julian Teufel; Florian Ringel; Marcus Bettstetter; Ingrid Hoepner; Michael Rasper; Jens Gempt; Julia Koeritzer; Friederike Schmidt-Graf; Bernhard Meyer; Christoph P Beier; Jürgen Schlegel
Journal:  Neuro Oncol       Date:  2012-11-06       Impact factor: 12.300

Review 7.  Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.

Authors:  Dagmar Beier; Joerg B Schulz; Christoph P Beier
Journal:  Mol Cancer       Date:  2011-10-11       Impact factor: 27.401

8.  The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.

Authors:  Laura Annovazzi; Valentina Caldera; Marta Mellai; Chiara Riganti; Luigi Battaglia; Daniela Chirio; Antonio Melcarne; Davide Schiffer
Journal:  Int J Oncol       Date:  2015-04-16       Impact factor: 5.650

9.  Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM.

Authors:  Nidhan K Biswas; Vikas Chandra; Neeta Sarkar-Roy; Tapojyoti Das; Rabindra N Bhattacharya; Laxmi N Tripathy; Sunandan K Basu; Shantanu Kumar; Subrata Das; Ankita Chatterjee; Ankur Mukherjee; Pryiadarshi Basu; Arindam Maitra; Ansuman Chattopadhyay; Analabha Basu; Surajit Dhara
Journal:  Sci Rep       Date:  2015-01-21       Impact factor: 4.379

10.  PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.

Authors:  Georg Karpel-Massler; Fresia Pareja; Pascaline Aimé; Chang Shu; Lily Chau; Mike-Andrew Westhoff; Marc-Eric Halatsch; John F Crary; Peter Canoll; Markus D Siegelin
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.